A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 29 May 2015
Price : $35 *
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2014 According to an Alnylam Pharmaceuticals media release, this study is intended to support the expansion of the APOLLO trial to include sites in Japan.